ATTO-2306 / Attovia Therap - LARVOL DELTA

Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026 (GlobeNewswire) - "Attovia will present four posters: three on ATTO-1310, a next generation anti-IL-31 ATTOBODY-based therapeutic, and one on ATTO-2306, a novel long-acting anti-IL-31 and IL-13 bispecific. The ATTO-1310 posters will highlight Phase 1a data in healthy volunteers, translational data advancing the understanding of IL-31 across pruritic skin diseases, and interim Phase 1b data in patients with high-itch atopic dermatitis (AD) or with chronic pruritus. The ATTO-2306 poster will feature new preclinical data."

P1 data • Preclinical • Atopic Dermatitis • Chronic Spontaneous Urticaria • Immunology • Prurigo Nodularis • Pruritus